Abstract: A method and system for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected lime. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin or the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.

Abstract: A system and method for use in iontophoretic anesthesia of a tympanic membrane are disclosed. The system generally includes an earplug and an electrode device. The earplug includes at least one sealing member for sealing the earplug in an ear canal. The sealing member includes microholes which vent fluid above a certain pressure threshold. A headset may connect the earplug to a second earplug. The method involves using the system on a human or animal subject.

Abstract: A method for determining a volume of ablated tissue is provided. The method includes the steps of: supplying energy to tissue to create an ablation volume therein; excising one or more slices of the tissue having a portion of the ablation volume therein; and subjecting at least a portion of the slice to a first contrast agent for a predetermined period of time, wherein the contrast agent is configured to color dead cells within the ablation volume.

Abstract: The present invention relates to a method of regulating or inducing specific physiological conditions or functions using one or more materials displayed on a nano-assembly matrix at high density in cells or in vivo. Specifically, the present invention relates to a method of effectively inducing specific physiological regulation in cells or in vivo by the high-density display of bioactive materials. According to the method of the invention, physiological regulation in cells or in vivo can be optionally induced by regulating the assembly and disassembly of nano assembly (unit) matrix or the display or trapping of specific materials on nano assembly (unit) matrix.

Abstract: The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol (rotigotine), their use as a medicament, for example for the treatment of CNS disorders like Parkinson Disease, RLS, fibromyalgia and/or depression, in particular through electromotive administration. The present invention relates to pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of rotigotine to at least one target tissue. The formulations are further characterized by good to excellent solubility of the salts in aqueous solutions.

Abstract: Provided herein are linear nucleic expression cassettes and methods of using same in a non-invasive method of vaccination. The method combines electroporation and linear DNA constructs encoding antigens to elicit antigen-specific immune responses.

Abstract: A method and composition for hyperthermally diagnosing and monitoring treatment of cells with photoacoustic sound and nanoparticles.

Abstract: A method and composition for hyperthermally diagnosing and monitoring treatment of cells with photoacoustic sound and nanoparticles. The heat (temperature) and photoacoustic sound wave production inside the target tissue is measured. The desired temperature is achieved using a laser and photoacoustic imaging technique. Hyperthermia treatment of tissue applies a heat source to kill cells without protein denaturation. The hyperthermia treatment may further comprise platelet-derived treatment. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally treat the tissue. The temperature to which the target site is treated ranges from about 39° C. to about 58° C., and may last from about 5 seconds to about 30 minutes. The composition which can be a liposome composition encapsulating the dye can be introduced to the bloodstream to flow through the target site.

Abstract: Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

Abstract: An iontophoretic drug delivery device storage apparatus and a method of using that device is disclosed. The device comprises a fluid reservoir, an electrode assembly and a tray apparatus. The fluid reservoir is capable of retaining a medicament and has a sealed fluid chamber defined by at least one seal. The seal includes a weaker region and a pinch-like configuration associated with that region such that application of pressure to the fluid reservoir breaks the weaker region of the seal, releasing the retained medicament. The electrode assembly comprises an active electrode, at least two passive electrodes a medicament carrying region, and a moat region around the medicament carrying region so that once fluid is delivered from the fluid reservoir to the electrode assembly the fluid is substantially retained in the medicament carrying means.

Abstract: A method and device to apply a cold plasma to a substance at a treatment surface of a patient to cause electroporation of the substance into cells of the patient. The substance can be previously applied to the treatment surface. Alternatively, the substance can be placed in a foam-like material within a tip that passes the cold plasma from the cold plasma device to the treatment area. The tip can be a cannula device with an aperture at the distal end. The cannula device can also have apertures along a portion of the length of the cannula device.

Abstract: A therapeutic agent delivery device and method for eluting a therapeutic agent to a target location are disclosed. The therapeutic agent delivery device may comprise a first conductive element, a second conductive element, and an electrochemical layer including a neurotoxin located between the first conductive element and the second conductive element. The first conductive element and the second conductive element are adapted to be connected to a voltage source. When the first conductive element and the second conductive element are connected to the voltage source, an electrochemical reaction occurs causing the neurotoxin to release from the electroactive layer and elute to a target location.

Abstract: The present invention includes methods and devices for delivering an active agent into the eye of a subject. One such device may include an anode assembly having an anode housing and an anode configured to electrically couple to a power source, the anode assembly being configured to contact and remain against a surface of the eye. The device may also include a cathode assembly having a cathode housing and a cathode configured to electrically couple to the power source, the cathode assembly being configured to contact and remain against the surface of the eye. Additionally, the device may include at least one active agent reservoir functionally associated with at least one of the anode assembly and the cathode assembly.

Abstract: Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Abstract: A method and system for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected time. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin of the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.

Abstract: Antibiotics are administered in a surgical site subcutaneously via a small or stab incision in the surgical field. Transcutaneous ultrasonic vibrations are applied across the surgical field, which is then opened in the usual manner, to thereby provide a surgical field which contains a vastly higher and more effective level of antibiotic. At the same time the underlying tissue is hydrated.

Abstract: An embodiment of a system includes a power source and at least two electrode assembles. The power source that an output current that alternates between a maximum current value and a minimum current value; a pair of electrode assemblies. Each electrode assembly is configured to be held in contact with a skin layer of a user. Additionally, each electrode assembly includes an electrode that is coupled to the power source to receive the output current from the power source. At least one of the electrode assemblies in the pair includes a medium that carries an active agent having a charge, the medium being provided on the at least one electrode assembly to enable the output current to repel the active agent into the skin layer for a duration in which the output current has a polarity that is the same as a polarity of the active agent.

Abstract: Medical devices comprising an electroactive polymer powered by a photovoltaic cell. In one embodiment, the medical device has an electroactive component comprising an electroactive polymer. The medical device further comprises a photovoltaic cell as a source of electrical power for electrically stimulating the electroactive polymer. The medical device further comprises a first electrode and a second electrode, both of which are electrically connected to the photovoltaic cell. The electroactive component covers over at least a portion of the first electrode. Also disclosed is a method of treating a patient using a medical device having an electroactive polymer powered by a photovoltaic cell.

Abstract: The present invention features a method of treating pores on the skin by applying to skin in need of such treatment a device including a housing having a skin contacting surface, a first conductive electrode, a second conductive electrode, and a carrier; wherein the first conductive electrode is in electric communication with the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the carrier is in communication with the skin contacting surface, and wherein the skin contacting surface is placed in contact with the skin.

Abstract: The invention provides compositions for inducing expression in hair cells, and provides methods of using these compositions for modulating cochlear expression. Such compositions are further useful in treatment of sensorineural hearing loss, e.g., increasing proliferation or survival of mechanosensory hair cells.

Abstract: Provided is a device for iontophoretic delivery of a drug to or into a tissue, including an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. Also provided is a method for iontophorectivally administering drug to or into a tissue, including determining a maximal allowed level of current density and preventing application of current density above the maximal allowed level.

Abstract: The invention relates generally to intradermal, transdermal, and/or transmembrane delivery of biologically active substances in the epidermis and/or through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular surface, tissue or membrane. The biologically active substances may have a molecular weight no less than about 5.8 kDa to about 2,500 kDa, such as Hyaluronic Acid (HA). The biologically active substances may be deposited in a dermal patch containing a red algae polysaccharide-based matrix, wherein the red algae polysaccharide is an extract of Chondrus crispus at 2% by weight of the dermal patch. The invention provides systems and methods for enhanced intradermal, transdermal, and/or transmembrane delivery of such biologically active substances using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes using those compositions and methods.

Abstract: Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a Y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles.

Abstract: An apparatus for the treatment and/or prevention of corneal diseases includes an applicator head. The applicator head includes a radiation source capable of exciting a non-toxic chromophore. A control is operable to activate the radiation source to radiate, wherein at least one of the following two conditions is met: the applicator head includes a sensor capable of measuring a signal dependent on a position of the applicator head relative to the cornea; or, the applicator head is configured to be in physical contact with the cornea. The control is operable to activate the radiation source to radiate depending on a signal measured by the sensor or to activate the radiation source when the applicator head touches the cornea, respectively.

Abstract: Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.

Abstract: The present invention provides a set of body slimming compositions, for application to a body before irradiating the body with a far-infrared ray in an atmosphere of 50° C. or thereabout. The slimming composition set includes a first external composition containing a cosmetic base, a Bacillus-fig-soybean fermented liquor, a Bacillus-Monascus-angelica-soybean fermented liquor, a Bacillus-longan-soybean fermented liquor, orizanol, tocopheryl acetate, macadamia nut oil, and glucosyl hesperidine, and a second external composition containing a cosmetic base, a Bacillus-persimmon-soybean fermented liquor, a Waltheria indica leaf extract, and ascorbyl tetrahexyldecanoate. The first external composition is applied to a lymphatic node region of the body, and the second external composition is applied to a slimming target region of the body. The composition set of the invention can activate lymph or lipase, whereby a remarkable body slimming effect can be attained.

Abstract: Apparatus and methods for implanting ocular implants in eyes are provided which include a bent cannula having a lumen extending therethrough, the lumen having a length and a diameter and being configured to receive an ocular implant. The ocular implant is made up of a plurality of substantially uniformly sized particles, preferably a plurality of uniformly sized microspheres, arranged in a one-by-one array along the length of the lumen. The apparatus further comprises a mechanism for delivering the implant through the distal end of the lumen and into the eye, preferably without the use of a liquid or gel carrier medium located in the lumen along with the implant.

Abstract: Electroporation devices are provided which include a forceps-type member carrying first and second electrodes and a grip member carrying a third electrode. The third electrode is independently movable with respect to the first and second electrodes in order to vary the spatial configuration of the electrical field generated by the device and thus enable an improved range of action and efficacy. Methods for carrying out electroporation with such devices are also provided.

Abstract: The present invention provides a device for iontophoretic delivery of a drug to on into a tissue, comprising an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. The present invention also provides a method for iontophorectivally administering drug to or into a tissue, comprising determination of a maximal allowed level of current density and preventing application of current density above the maximal allowed level.

Abstract: The present invention provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R1 and R2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue, wherein growth of the tumor is inhibited.

Abstract: This application is directed to a method of treating a patient with acne by applying a photodynamic agent to skin having acne lesions, waiting at least 12 hours, and then exposing the skin to which the photodynamic agent has been applied to light that causes an activation reaction.

Abstract: Systems and methods are providing for treating a patient with continuous low irradiance photodynamic therapy. A disclosed method includes applying a photosensitizer to the patient; applying a conformable skin facing light applicator to the patient; and providing continuous low irradiance photodynamic therapy through the light applicator. A disclosed system includes a light applicator having a fiber optic cloth. The light applicator is conformable so that it can be worn against a patient's skin and the fiber optic cloth has a two dimensional surface that emits light in a direction toward a patient's skin. In this aspect, the power of the light emitted from the two dimensional surface in a direction toward a patient's skin is less than or equal to about 5 mW/cm2.

Abstract: The present disclosure relates systems and methods for tissue remodeling, that ameliorate fat deposits by disrupting adipocytes through low-temperature extended treatment time approaches, in conjunction with selective treatment and/or localized cooling of the treatment site to prevent or minimize damage to non-target tissues.

Abstract: The present invention provides drug conjugates comprising 5-aminolevulinic acid (ALA), an aldehyde and a carboxylic acid that may function as a histone deacetylase inhibitor (HDACI). These conjugates may serve as co-drugs which release a plurality of active species in vivo. The novel drug conjugates may be used, for the treatment or prevention of cancer in PDT-dependent and/or PDT-independent (nonPDT) treatments, as well as for cosmetic uses. In addition the present invention provides novel uses for both the novel and known compounds. According to some embodiments, the present invention provides drug conjugates (co-drugs) comprising (i) ALA, (ii) an aldehyde and (iii) a carboxylic acid that may function as a histone deacetylase inhibitor (HDACO for the treatment of anemia and/or for the induction of erythropoiesis.

Abstract: The present invention includes methods and devices for delivering an active agent into the eye of a subject. One such device may include an anode assembly having an anode housing and an anode configured to electrically couple to a power source, the anode assembly being configured to contact and remain against a surface of the eye. The device may also include a cathode assembly having a cathode housing and a cathode configured to electrically couple to the power source, the cathode assembly being configured to contact and remain against the surface of the eye. Additionally, the device may include at least one active agent reservoir functionally associated with at least one of the anode assembly and the cathode assembly.

Abstract: Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy).

Abstract: Provided are nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans.

Abstract: This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the ? amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents.

Abstract: Provided are novel nanostructures comprising hollow nanospheres (HGNs) and nanotubes for use as chemical sensors, molecular specific photothermal coupling agents, and photothermal ablation compounds. The nanostructures can be used in electromagnetic radiation-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.

Abstract: An apparatus for controlled healing of ocular erosions is described. The apparatus comprising; an optical surface comprising an energizable controller capable of being programmed to transmit energy from an energy source onto/into an ocular surface, through the use of a current generator in electrical connection with energy emitting contacts capable of transmitting an electric field. The controller, current generator and energy emitting contacts are biocompatible or encapsulated by a conductive biocompatible layer to allow positioning of said apparatus in an ocular surface.

Abstract: Provided are nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans.

Abstract: A device and methods for increasing the permeability of the skin's surface to fluid and/or drug delivery is described. The device comprises an abrasive media to remove the outer layer of the stratum corneum, while at the same time applying an electric current that stimulates the skin under the stratum corneum, and delivers fluids from a supply reservoir. The device may also have a vacuum function which evacuates fluid and skin debris from the surface of the skin and delivers the evacuated fluid and skin debris to a waste (or collection) container.

Abstract: Methods and systems for treating skin for aesthetic or health purposes are described. According to various embodiments, photoresponsive materials and light are delivered in a controlled fashion to produce a patterned distribution of a material in the skin.

Abstract: The present invention relates to the field of optical imaging and therapeutics. More particularly, embodiments of the present invention provide minimally-invasive Fiberoptic Microneedle Devices (FMDs) for light-based therapeutics, which physically penetrate tissue and deliver light directly into the target area below the skin surface. Embodiments of the invention enable depth-selective and deep photothermal therapeutics and include methods of treating cancer, methods of re-shaping or removing adipose tissue, and methods of delivering drugs or co-delivering drugs and energy to selected tissue.

Abstract: Methods and systems for treating skin for aesthetic, functional, health or other purposes are described. According to various embodiments, materials are delivered to or formed in or on the skin at multiple depths or heights in a pattern to form a hologram in or on the skin.

Abstract: The present disclosure relates to a phototherapy device that can deliver light to tissues to activate photoactive agents that have been applied to the tissues or that are included within a fiber optic tip member of the device which may be coupled to a light source using a sleeve. The present disclosure also relates to methods of phototherapy using the phototherapy device such as anti-bactericidal treatment, anti-fungal treatment, anti-parasitic treatment, anti-viral treatment.

Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.

Abstract: Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Abstract: The present invention relates to substances, to electroluminescent devices comprising these substances, and to the use thereof.

Abstract: The subject matter of the present invention is a sterile liquid composition dedicated to administration into or through the skin and/or the lips, wherein said composition comprises, in a physiologically acceptable medium, at least one photo-crosslinkable compound, wherein said compound comprises at least one activated photo-dimerizable group having at least one activated double bond and selected from photo-dimerizable groups carrying a stilbazolium function of formula (Ia) or (Ib) and wherein the photo-dimerizable groups carry a styrylazolium function of formula (II), the photo-dimerizable group(s) being carried by a partially or totally hydrolysed poly(vinyl acetate) polymer, a polysaccharide or a polyvinyl alcohol